On December 5, 2025, investment firm Guggenheim reaffirmed its 'buy' rating on Eli Lilly and Company shares, setting a price target of $1,163.00. This reflects continued confidence in the company's growth trajectory and product pipeline. In addition to the analyst rating, a Zacks Equity Research industry outlook highlighted Eli Lilly as a key large pharmaceutical stock to watch. The report emphasized the significant success and rapid demand growth for its tirzepatide medicines, Mounjaro for diabetes and Zepbound for weight loss, which are considered major drivers of the company's strong performance and positive future prospects.